Agape ATP (NASDAQ:ATPC – Get Free Report) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Sunday.
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Agape ATP in a report on Wednesday, January 21st. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has an average rating of “Sell”.
Agape ATP Price Performance
Institutional Inflows and Outflows
A hedge fund recently raised its stake in Agape ATP stock. Citadel Advisors LLC increased its stake in shares of Agape ATP Corporation (NASDAQ:ATPC – Free Report) by 95.7% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 65,130 shares of the company’s stock after buying an additional 31,849 shares during the period. Citadel Advisors LLC owned about 0.13% of Agape ATP worth $82,000 as of its most recent filing with the Securities and Exchange Commission. 0.01% of the stock is currently owned by institutional investors.
About Agape ATP
Agape ATP Corporation, an investment holding company, supplies health and wellness products and health solution advisory services in Malaysia. It offers four series of programs that consist of various services and products under the ATP Zeta Health Program, ÉNERGÉTIQUE, BEAUNIQUE, and E.A.T.S. names. The company's products include ATP1s Survivor Select that contains various essential nutrients required by the human body to maintain normal metabolism; ATP3 Ionized Cal-Mag, a calcium and magnesium minerals supplement; ATP4 Omega Blend, an oil blend that provides a bio-effective balance of essential fatty acids, omega 3, and omega 6; ATP5 BetaMaxx, a natural immune enhancer; AGN-Vege Fruit Fiber, a nutrition-based formulation for intestines and stomach; AGP1-Iron to improve iron deficiency anemia; and YFA-Young Formula, an anti-aging and youthful maintenance supplement.
Recommended Stories
Receive News & Ratings for Agape ATP Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agape ATP and related companies with MarketBeat.com's FREE daily email newsletter.
